Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by Super63on Jan 19, 2020 8:24am

318 Views

Post# 30570576

Thank you again Francine

I like everyone else was unaware of the 2012 study on the diet used in Trilogy. That study showed reduction of TG of 22%. Some now suggest that much of Capre's reduction has been from this diet and is therefore ineffective. I noticed that the diet was not at the top of your possible placebo culprits list. Was this fish diet utilized in previous Capre trials? I believe a fish diet is not a longterm answer for patients and like the show "The Biggest Loser" the biggest gains come in the first weeks. Appreciate ya!

<< Previous

Bullboard Posts

Next >>

FDA committee rejects MDMA drug, discounting psychedelic stocks